Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

In Q4, Regeneron reported EPS at $12.07, up from $11.86 in the same quarter last year. This print beat analysts’ estimates by 7.8%. Over the next 12 months, Wall Street expects Regeneron’s ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

[content-module:Forecast|NASDAQ:REGN] Regeneron reported Q4 2024 EPS of $12.07, beating consensus estimates by 71 cents.

Regeneron posted Q4 adjusted EPS of $12.07, beating the $11.29 consensus. Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew 2% Y/Y to $1.49B ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported fourth-quarter earnings of $917.7 million. On a per-share basis, the Tarrytown ...

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

Regeneron Pharmaceuticals ... the company grew its total revenue by 10% year-over-year to $3.8 billion in fiscal Q4 2024. The positive performance was primarily due to Dupixent, which recorded ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.